Study of Tumor Treatment Vaccine Combined With PD-1PD-L1 Inhibitors for Advanced Solid Tumors That Have Relapsed or Are Resistant to Treatment

What this Trial Is About

Researchers are evaluating the clinical efficacy of the Tumour Treatment Vaccine TTV combined with PD-1PD-L1 inhibitors in treating relapsed and refractory advanced solid tumors. Previous studies showed that TTV can enhance the anti-tumor effect of immune checkpoint inhibitor therapy, reaching a tumor suppression rate of 75.96% when combined with PD-1 inhibitors. This study aims to assess this combination treatment from a clinical perspective in patients with advanced solid tumors. The treatment involves administering the tumor treatment vaccine TTV by deep subcutaneous injection into the arm or near the tumor. PD-1L1 inhibitors are used according to their approved indications. The initial TTV dose is 1 ml per injection, which may be increased to 2.5-4.0 ml depending on patient response. The timing between injections can be adjusted based on the patients condition and reaction. This is an interventional study with an experimental group receiving the combined treatment. Participants will be monitored for tumor relief immediately after the last treatment. The study includes evaluations of measurable lesions using standard criteria and assessments of overall health and treatment response. Participants must comply with follow-up visits and provide informed consent. The study runs from May 2024 to December 2027 and includes safety monitoring and tumor response measurements throughout the treatment period.

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours